DK2464343T3 - System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol - Google Patents

System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol Download PDF

Info

Publication number
DK2464343T3
DK2464343T3 DK10808467.4T DK10808467T DK2464343T3 DK 2464343 T3 DK2464343 T3 DK 2464343T3 DK 10808467 T DK10808467 T DK 10808467T DK 2464343 T3 DK2464343 T3 DK 2464343T3
Authority
DK
Denmark
Prior art keywords
cholesterol
administration
containing phospholipid
medication containing
ophthalmic medication
Prior art date
Application number
DK10808467.4T
Other languages
English (en)
Inventor
Keelung Hong
Sheue-Fang Shih
Po-Chun Chang
Yun-Long Tseng
Luke S S Guo
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Application granted granted Critical
Publication of DK2464343T3 publication Critical patent/DK2464343T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK10808467.4T 2009-08-10 2010-01-29 System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol DK2464343T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/538,435 US8956600B2 (en) 2009-08-10 2009-08-10 Ophthalmic drug delivery system containing phospholipid and cholesterol
PCT/US2010/022487 WO2011019410A1 (en) 2009-08-10 2010-01-29 Ophthalmic drug delivery system containing phospholipid and cholesterol

Publications (1)

Publication Number Publication Date
DK2464343T3 true DK2464343T3 (da) 2019-01-02

Family

ID=43534994

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10808467.4T DK2464343T3 (da) 2009-08-10 2010-01-29 System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol
DK14180435.1T DK2813229T3 (da) 2009-08-10 2010-01-29 System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14180435.1T DK2813229T3 (da) 2009-08-10 2010-01-29 System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol

Country Status (18)

Country Link
US (4) US8956600B2 (da)
EP (3) EP2813229B1 (da)
JP (2) JP5816623B2 (da)
KR (2) KR101921852B1 (da)
CN (2) CN105148278B (da)
AU (1) AU2010282983B2 (da)
BR (1) BR112012002981B8 (da)
CA (1) CA2769929C (da)
CY (2) CY1121472T1 (da)
DK (2) DK2464343T3 (da)
ES (2) ES2699178T3 (da)
HK (2) HK1172564A1 (da)
NZ (2) NZ623450A (da)
PT (2) PT2464343T (da)
RU (1) RU2572213C2 (da)
TW (1) TWI515008B (da)
WO (1) WO2011019410A1 (da)
ZA (1) ZA201201034B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
IN2014DN06911A (da) * 2012-01-31 2015-05-15 Santen Pharmaceutical Co Ltd
JP6231995B2 (ja) * 2012-02-10 2017-11-15 タイワン リポソーム カンパニー リミテッド 眼の疾患の合併症を低減するための薬学的組成物
JP6044920B2 (ja) * 2012-03-27 2016-12-14 国立研究開発法人農業・食品産業技術総合研究機構 酸化ｌｄｌ受容体に作用するリポソーム
SG10201610887WA (en) * 2012-07-05 2017-02-27 Taiwan Liposome Co Ltd Methods of treating arthritis
JP6209791B2 (ja) * 2012-07-17 2017-10-11 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 白内障を処置するためのα−クリスタリン凝集の阻害剤
CA2879597C (en) * 2012-08-21 2021-01-12 Opko Pharmaceuticals, Llc Ophthalmic liposome formulations for treating posterior segment disease
US11458199B2 (en) 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
EA022183B1 (ru) * 2012-12-24 2015-11-30 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы цитохрома с
EP2950785A4 (en) 2013-02-04 2016-09-21 Univ Notre Dame Du Lac NANOPARTICLE-drug delivery systems
JPWO2014196621A1 (ja) * 2013-06-07 2017-02-23 Ｋｔｎバイオテック株式会社 抗癌剤
US9895312B2 (en) * 2014-04-08 2018-02-20 Pablo E. Vivas-Mejia Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
AU2016381964B2 (en) * 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
ES2863659T3 (es) * 2016-01-07 2021-10-11 Univ Western Health Sciences Formulaciones para el tratamiento del cáncer de vejiga
SG11201809490YA (en) * 2016-04-29 2018-11-29 Enceladus Pharmaceuticals B V Liposomal corticosteroids for topical injection in inflamed lesions or areas
EP3500312B1 (en) * 2016-08-18 2024-04-10 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN110743035A (zh) * 2019-11-06 2020-02-04 广西大学 一种智能抗菌的水凝胶的制备方法及其应用
GB201917487D0 (en) * 2019-11-29 2020-01-15 Oxular Ltd Methods for the treatment of retinoblastoma
TW202302115A (zh) 2021-03-05 2023-01-16 台灣微脂體股份有限公司 具有降低副作用的藥學組成物及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550960A (en) * 1895-12-10 Island
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
JPH07503952A (ja) 1992-02-12 1995-04-27 ジヤンセン・シラグ・ソチエタ・ペル・アチオニ リポソームピロキシカム組成物
TR199701683A3 (tr) 1997-12-18 2001-06-21 Eldem Tuerkan Oküler ve parenteral polimer kapli lipozomal ilaç tasiyici sistemler.
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
DE10032627A1 (de) 2000-07-07 2002-01-17 Km Europa Metal Ag Verwendung einer Kupfer-Nickel-Legierung
IL159334A0 (en) 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US20040224010A1 (en) 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
JP5216002B2 (ja) * 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US20080118500A1 (en) * 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Also Published As

Publication number Publication date
EP2464343A1 (en) 2012-06-20
CY1121472T1 (el) 2020-05-29
KR20170107106A (ko) 2017-09-22
TWI515008B (zh) 2016-01-01
JP5816623B2 (ja) 2015-11-18
ZA201201034B (en) 2015-06-24
CN105148278B (zh) 2019-11-05
TW201105350A (en) 2011-02-16
RU2012108888A (ru) 2013-09-20
DK2813229T3 (da) 2018-12-17
EP2464343A4 (en) 2013-01-23
BR112012002981A2 (pt) 2016-04-19
CN102573800B (zh) 2015-09-30
US10660960B2 (en) 2020-05-26
KR101921852B1 (ko) 2018-11-23
US20200289652A1 (en) 2020-09-17
CY1121467T1 (el) 2020-05-29
EP2464343B1 (en) 2018-08-29
US20180169248A1 (en) 2018-06-21
EP3275445A1 (en) 2018-01-31
PT2813229T (pt) 2018-11-30
US20150147320A1 (en) 2015-05-28
US9987360B2 (en) 2018-06-05
CA2769929C (en) 2018-01-02
CN102573800A (zh) 2012-07-11
ES2699178T3 (es) 2019-02-07
AU2010282983A1 (en) 2012-03-01
RU2572213C2 (ru) 2015-12-27
BR112012002981B1 (pt) 2020-12-01
NZ598656A (en) 2014-04-30
WO2011019410A1 (en) 2011-02-17
NZ623450A (en) 2015-06-26
JP2013501786A (ja) 2013-01-17
KR20120083316A (ko) 2012-07-25
PT2464343T (pt) 2018-12-05
US11771766B2 (en) 2023-10-03
ES2699249T3 (es) 2019-02-08
EP2813229A1 (en) 2014-12-17
CA2769929A1 (en) 2011-02-17
US8956600B2 (en) 2015-02-17
CN105148278A (zh) 2015-12-16
EP2813229B1 (en) 2018-08-29
KR101787775B1 (ko) 2017-10-18
AU2010282983B2 (en) 2016-09-22
BR112012002981B8 (pt) 2021-05-25
HK1214946A1 (zh) 2016-08-12
JP2015164961A (ja) 2015-09-17
JP6243874B2 (ja) 2017-12-06
HK1172564A1 (zh) 2013-04-26
US20110033468A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
DK2464343T3 (da) System til indgivelse af oftalmisk medicin indeholdende phospholipid og kolesterol
DK3527241T3 (da) Indretning til administration af lægemiddel
DK2254590T3 (da) Fremgangsmåder og præparater til oral administration af insulin
DK2493474T3 (da) Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler
DK2275086T3 (da) Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
DK2714135T3 (da) Medikamentadministrationsanordning og fremgangsmåde til styring af anordningen
DK2563450T3 (da) Apparat til administration af rheumatoid-arthritis-medikament
BRPI1012246A2 (pt) composição farmacêutica contendo um fármaco e sirna
IL219910A0 (en) Device and method for delivery of two or more drug agents
DK3461478T3 (da) Synkbar enhed til levering af lægemidler
DK2482899T3 (da) Konstruktion til indretning til indgivelse af lægemiddel
DK2493531T4 (da) Lægemiddelfremføringsindretninger og fremgangsmåde til samling
DK2326371T3 (da) Systemer til indgift af medicin til patienter med rheumatoid arthritis
EP2213318A4 (en) DRUG SOLUTION DELIVERY SYSTEM AND DRUG SOLUTION ADMINISTRATION CANNULA
IL202070A0 (en) Inline liquid drug medical device
DK2373364T3 (da) Medikamentadministrationsanordning og fremgangsmåde til drift af en medikamentadministrationsanordning
DK2651410T3 (da) Transdermalt terapeutisk system til administration af et aktivstof
DK2506712T3 (da) Morfinanderivater til behandling af lægemiddeloverdosering
DK2299977T3 (da) Liposomer til lægemiddelafgivelse og fremgangsmåder til fremstilling heraf
DK2504948T3 (da) System og fremgangsmåde til administration og distribution af diagnostisk billeddannelse
DK3603704T3 (da) Indgivelse af medikament
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2482881T3 (da) Mekanisme til indretning til indlevering af lægemiddel
DK3005986T3 (da) Infusion af lægemidler
DK2621477T3 (da) Oral farmaceutisk tablet til kontrolleret afgivelse af mesalazin og fremgangsmåde til opnåelse deraf